Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies315
  • 7D-2.6%
  • 3M-1.6%
  • 1Y37.2%
  • YTD-0.7%

Over the last 7 days, the Pharma industry has dropped 2.6%, driven by a pullback from Eli Lilly of 5.1%. In the past year, the industry has gained 37%. Looking forward, earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026US$2.3tUS$408.1bUS$66.7b16.8x34x5.6x
Sat, 14 Mar 2026US$2.3tUS$406.1bUS$72.0b17.4x31.8x5.6x
Mon, 09 Feb 2026US$2.4tUS$411.7bUS$74.2b21.2x32.4x5.8x
Wed, 07 Jan 2026US$2.2tUS$402.6bUS$71.5b19.6x31x5.5x
Fri, 05 Dec 2025US$2.2tUS$402.7bUS$71.4b19.7x30.5x5.4x
Sun, 02 Nov 2025US$1.9tUS$396.3bUS$71.7b18.1x26.8x4.8x
Tue, 30 Sep 2025US$1.7tUS$387.9bUS$60.9b18.7x28.7x4.5x
Thu, 28 Aug 2025US$1.8tUS$387.8bUS$61.0b19.9x29x4.6x
Sat, 26 Jul 2025US$1.8tUS$384.0bUS$62.1b18.2x29.2x4.7x
Mon, 23 Jun 2025US$1.7tUS$382.7bUS$61.2b17.9x27.9x4.5x
Wed, 21 May 2025US$1.7tUS$382.6bUS$61.2b17.6x27.5x4.4x
Fri, 18 Apr 2025US$1.6tUS$380.5bUS$48.4b16.1x33.8x4.3x
Sun, 16 Mar 2025US$1.8tUS$380.5bUS$35.2b16.1x52.6x4.9x
Tue, 11 Feb 2025US$1.9tUS$380.7bUS$39.1b18.3x47.9x4.9x
Thu, 09 Jan 2025US$1.8tUS$369.3bUS$31.3b17.8x57.5x4.9x
Sat, 07 Dec 2024US$1.9tUS$373.8bUS$30.6b19.3x61.2x5x
Mon, 04 Nov 2024US$1.9tUS$373.2bUS$29.3b19.6x64.9x5.1x
Wed, 02 Oct 2024US$2.0tUS$364.1bUS$25.2b19.4x79.1x5.5x
Fri, 30 Aug 2024US$2.1tUS$363.3bUS$19.2b18x107x5.6x
Sun, 28 Jul 2024US$1.9tUS$357.5bUS$12.8b16.3x152.1x5.4x
Tue, 25 Jun 2024US$2.0tUS$358.2bUS$14.1b16.3x139x5.5x
Thu, 23 May 2024US$1.9tUS$358.3bUS$14.1b18.2x134.8x5.3x
Sat, 20 Apr 2024US$1.8tUS$357.7bUS$29.8b20.3x60.2x5x
Mon, 18 Mar 2024US$1.9tUS$355.4bUS$22.5b19.8x82.7x5.2x
Wed, 14 Feb 2024US$1.8tUS$354.9bUS$22.8b31x80.9x5.2x
Fri, 12 Jan 2024US$1.8tUS$375.2bUS$33.9b26.6x52.4x4.7x
Sun, 10 Dec 2023US$1.7tUS$375.1bUS$33.9b26.6x48.9x4.4x
Tue, 07 Nov 2023US$1.6tUS$376.9bUS$33.9b18.9x48.1x4.3x
Thu, 05 Oct 2023US$1.6tUS$381.8bUS$43.8b18.5x37.6x4.3x
Sat, 02 Sep 2023US$1.7tUS$381.4bUS$43.7b19.6x39.7x4.5x
Mon, 31 Jul 2023US$1.7tUS$393.6bUS$61.5b18.5x28x4.4x
Wed, 28 Jun 2023US$1.7tUS$392.8bUS$60.1b18.9x29x4.4x
Fri, 26 May 2023US$1.7tUS$392.9bUS$60.5b18.3x28.1x4.3x
Sun, 23 Apr 2023US$1.7tUS$402.6bUS$63.3b17.8x26.3x4.1x
Price to Earnings Ratio

26.3x


Total Market Cap: US$1.7tTotal Earnings: US$63.3bTotal Revenue: US$402.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 34.0x which is lower than its 3-year average PE of 53.7x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.42%
Healthcare-0.18%
Pharma-2.61%
Pharma-2.61%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TEVA Teva Pharmaceutical IndustriesUS$31.613.6%
+US$1.3b		135.4%PE26.1x
OGN OrganonUS$9.2157.2%
+US$872.1m		-14.9%PE12.8x
MANE VeradermicsUS$80.5038.7%
+US$838.7m		n/aPE-36.1x
AXSM Axsome TherapeuticsUS$184.186.3%
+US$562.2m		76.3%PS14.8x
RGC Regencell Bioscience HoldingsUS$29.813.2%
+US$459.9m		4,057.0%PB3032.9x

Latest News

LLY
US$905.03
Eli Lilly
7D
-5.1%
1Y
23.2%
RPRX
US$48.70
Royalty Pharma
7D
1.7%
1Y
51.3%
JNJ
US$238.67
Johnson & Johnson
7D
-1.1%
1Y
55.1%
TEVA
US$31.61
Teva Pharmaceutical Industries
7D
3.6%
1Y
135.4%

Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy

Apr 14
MRK
US$117.90
Merck
7D
-4.3%
1Y
54.2%
AXSM
US$184.18
Axsome Therapeutics
7D
6.3%
1Y
76.3%

Axsome Is Priced For Perfection Ahead Of Auvelity's Alzheimer's Agitation Decision

Apr 13
OGN
US$9.21
Organon
7D
57.2%
1Y
-14.9%

Organon Takeover At $15? Probably Not, Here's Why

Apr 13
ZTS
US$120.76
Zoetis
7D
0.8%
1Y
-17.7%
ELAN
US$23.23
Elanco Animal Health
7D
-1.6%
1Y
186.8%
BMY
US$57.89
Bristol-Myers Squibb
7D
-2.2%
1Y
17.3%
PFE
US$27.19
Pfizer
7D
-1.0%
1Y
23.4%

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
LGND
US$225.09
Ligand Pharmaceuticals
7D
8.2%
1Y
115.2%

LGND: Royalty Pipeline And Phase 3 Progress Will Drive Future Upside

Analysts have nudged their price target for Ligand Pharmaceuticals to $245.10 from $244.50, reflecting updated views on higher potential revenue growth, a much wider projected profit margin, and a lower future P/E assumption in recent research. Analyst Commentary Recent research on Ligand Pharmaceuticals has been active, with several firms adjusting price targets and reiterating positive views on the company’s royalty driven model and pipeline exposure.
PAHC
US$55.01
Phibro Animal Health
7D
-6.2%
1Y
226.9%

PAHC: Future Returns Will Rely On Achieving Aggressive Margin Outlook

Narrative Update on Phibro Animal Health Analysts lifted their price target on Phibro Animal Health by $6 to $38, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. Analyst Commentary Recent commentary around Phibro Animal Health has been mixed, with some research pointing to upside potential and others flagging reasons to be more cautious.
RGC
US$29.81
Regencell Bioscience Holdings
7D
3.2%
1Y
4,057.0%
BLTE
US$168.76
Belite Bio
7D
-5.6%
1Y
194.6%

Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech

Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?
MANE
US$80.50
Veradermics
7D
38.7%
1Y
n/a